Privately-held biotech firm MacroGenics has signed an agreement with Gilead Sciences to develop and produce Dual-Affinity Re-Targeting (DART) next-generation  antibody therapeutics, according to a press release on MacroGenics's site.

MacroGenics's deal with Gilead could be worth  up to more than $1.1 billion in payouts for the company if the DART program hits on all four of its milestones. MacroGenics may also receive royalties on any future sales that the program produces.

Gilead's Senior Vice President of Oncology and Inflammation Therapeutics, Dr. Roy D. Baynes,  explained Gilead's aim in the deal, saying:

This partnership underscores Gilead's commitment to developing innovative therapies that address significant unmet medical needs for patients with cancer and other life-threatening diseases.


Shares of Gilead rose more than 1.5% on Monday.

The article Gilead, MacroGenics Ink Antibody Licensing Deal originally appeared on Fool.com.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

What Is Your Risk Tolerance?

Answer the question "What type of investor am I?".

View Course »

Asset Allocation

Learn the most important step in structuring an investment portfolio.

View Course »

Add a Comment

*0 / 3000 Character Maximum